Metopirone (Metyrapone)

Metyrapone, the active ingredient in Metopirone, is a steroidogenesis inhibitor presented as an oral formulation for oral use. It is used in the diagnostic testing of adrenal insufficiency and in the treatment of Cushing's syndrome in adults.

GNH USA supplies Metopirone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metopirone acts on adrenal steroidogenesis and is employed in specific endocrine conditions.

Diagnostic testing of adrenal insufficiency: helps assess cortisol production capacity during ACTH stimulation. Cushing's syndrome: reduces excess cortisol synthesis to improve clinical signs. Adrenal function testing: used to evaluate the integrity of the hypothalamic‑pituitary‑adrenal axis.

Metyrapone may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Nausea or vomiting - Dizziness or headache - Fatigue or mild abdominal discomfort - Transient hypertension - Mild hypokalemia

Serious or Rare Side Effects: - Acute adrenal insufficiency - Severe hypertension or hypertensive crisis - Significant electrolyte disturbances (e.g., severe hypokalemia) - Allergic reactions including rash or anaphylaxis - Elevated liver enzymes or hepatic dysfunction

Before initiating Metopirone, several safety considerations should be reviewed.

Dose adjustment: monitor cortisol levels and adjust dosage as clinically indicated. Pregnancy: safety not established; use only if potential benefit justifies the risk. Breastfeeding: unknown excretion; weigh maternal benefit against possible infant exposure. Concomitant glucocorticoids: may mask signs of adrenal insufficiency. Drug interactions: review all concurrent medications for potential interactions. Store at ambient temperature: keep in the original container, protect from moisture and light.

Metyrapone can interact with several drugs that affect steroid metabolism or adrenal function.

Major Interactions (Avoid): - Ketoconazole: additive inhibition of steroidogenesis may cause severe adrenal suppression. - Glucocorticoids administered concurrently: may mask adrenal insufficiency symptoms. - Rifampin: induces hepatic enzymes, potentially reducing metyrapone efficacy.

Moderate Interactions (Monitor Closely): - Carbamazepine: enzyme induction may lower drug levels. - Phenobarbital: may decrease therapeutic effect through increased metabolism.